Søgeresultater - Gautam Borthakur
- Showing 1 - 20 results of 198
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia af Alison Gardner, Gloria Mattiuzzi, Stefan Faderl, Gautam Borthakur, Guillermo Garcia‐Manero, Sherry Pierce, Mark Brandt, Elihu H. Estey
Udgivet 2008Artigo -
9
-
10
-
11
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chron... af Constantine S. Tam, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam Borthakur, Susan O’Brien, Farhad Ravandi, Jenny Shan, Jorge E. Cortés
Udgivet 2008Artigo -
12
-
13
The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations af Weiguo Zhang, Gautam Borthakur, Gao Chen, Ye Chen, Hong Mu, Vivian Ruvolo, K. Nomoto, Nanding Zhao, Marina Konopleva, Michael Andreeff
Udgivet 2016Artigo -
14
Reversal of Acquired Drug Resistance in <i>FLT3</i>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies af Weiguo Zhang, Gao Chen, Marina Konopleva, Ye Chen, Rodrigo Jácamo, Gautam Borthakur, Jorge E. Cortés, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff
Udgivet 2014Artigo -
15
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 af Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Nicholas J. Short, Gautam Borthakur, Elias Jabbour, Hagop M. Kantarjian
Udgivet 2021Artigo -
16
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy af Dushyant Verma, Hagop M. Kantarjian, Jianqin Shan, Susan O’Brien, Zeev Estrov, Guillermo Garcia‐Manero, Charles Koller, Gautam Borthakur, Jorge E. Cortés
Udgivet 2010Artigo -
17
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy af Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Megan Breeden, Guillermo Garcia‐Manero, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortés
Udgivet 2008Artigo -
18
Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients af Peter P. Ruvolo, Yi Hua Qui, Kevin R. Coombes, Ningyan Zhang, Vivian Ruvolo, Gautam Borthakur, Marina Konopleva, Michael Andreeff, Steven M. Kornblau
Udgivet 2011Artigo -
19
-
20
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment af Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jorge E. Cortés, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey
Udgivet 2011Artigo
Søgeredskaber:
Relaterede emner
Medicine
Internal medicine
Oncology
Myeloid leukemia
Gene
Leukemia
Gastroenterology
Biology
Biochemistry
Chemotherapy
Chemistry
DNA methylation
Gene expression
Bone marrow
Cancer research
Genetics
Immunology
Cytarabine
Cancer
Myeloid
Chronic lymphocytic leukemia
Surgery
Azacitidine
Venetoclax
Decitabine
Imatinib
Myelodysplastic syndromes
Pharmacology
Adverse effect
Imatinib mesylate